-transparent.png){kind=logo}
BACKGROUND Neuropeptides are likely to be implicated in the pathophysiology of allergen-induced airway responses. However, upon release in the airways, neuropeptides are potentially inactivated by neutral endopeptidase (NEP). OBJECTIVE We hypothesized that NEP-inhibition by inhaled thiorphan (TH) would increase allergen-induced early (EAR) and late (LAR) asthmatic responses, and allergen-induced airway hyperresponsiveness to histamine in asthmatic subjects in vivo. The dose and dosing intervals of TH were derived from previous pharmacokinetic and dose-finding studies. METHODS Nine non-smoking, atopic, asthmatic men with dual asthmatic responses to inhaled house-dust mite extract participated in a double-blind, placebo-controlled, cross-over study. During each study period PC20 histamine was measured 24 h before, and 3 and 24 h post-allergen. TH (1.25 mg/mL, 0.5 mL) or placebo (P) were aerosolized pre-allergen, and three times at 2 h intervals post-allergen (total dose of TH: 2.5 mg). Forced expiratory volume in one second (FEV1) was recorded and expressed as percentage fall from baseline. The EAR (0-3 h) and the LAR (3-8 h) were defined as maximum percentage fall from the pre-allergen baseline and as corresponding areas under the time-response curves (AUC). RESULTS As compared with P, TH failed to induce an acute effect on FEV1 at any of the timepoints (P > 0.08). There was no significant difference between P and TH in the EAR and the LAR: neither in terms of maximum percentage fall from baseline (mean +/- SEM: EAR: 22.3 +/- 4.7% (P) and 20.4 +/- 4.1% (TH), P = 0.75; LAR: 25.2 +/- 4.7% (P) and 26.4 +/- 5.8% (TH), P = 0.77) nor in terms of AUC (P = 0.76). Correspondingly, the changes in PC20 histamine were not different between the two treatments (P > 0.40). CONCLUSIONS We conclude that four adequate doses of the inhaled NEP-inhibitor, thiorphan, failed to potentiate allergen-induced airway responses in asthma. These results suggest that either neuropeptides do not play a predominant role in allergen-induced airway responses, or that allergen challenge induces NEP-dysfunction in humans in vivo.
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
June 2004,
Chest,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
September 1999,
American journal of respiratory and critical care medicine,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
July 1991,
Lancet (London, England),
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
December 1997,
American journal of respiratory and critical care medicine,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
February 1993,
Respiratory medicine,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
August 2011,
Allergy,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
January 1994,
Lancet (London, England),
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
November 1996,
Thorax,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
July 2022,
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Z Diamant, and
H Van der Veen, and
E A Kuijpers, and
P F Bakker, and
P J Sterk
January 2007,
Canadian respiratory journal,
